Rilzabrutinib, a reversible BTK inhibitor, is also under investigation in patients with idiopathic warm AIHA in a multicenter, phase 2b Study (Table 2); however, the results are not yet available. The gene discussed is BTK; the disease is autoimmune hemolytic anemia.